CD163 and diabetes mellitus: These findings suggest not only the possible use of monocyte CD163 as a novel surrogate marker for insulin resistance in diabetes and/or obesity but also provide insight into the pathophysiological role of monocyte CD163 in the development of insulin resistance states.